Genetics of Hypertrophic cardiomyopathy

Current Opinion in Cardiology

Volumn 25, Issue 3, 2010, Pages 205-209

  Konno, Tetsuo ^a   Chang, Stephen ^a   Seidman, Jonathan G ^a   Seidman, Christine E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Gene mutation; Hypertrophic cardiomyopathy; Sarcomere

Indexed keywords

ALPHA TROPOMYOSIN; CALCINEURIN; CALCIUM ION; CALMODULIN; CONNECTIN; CYCLOSPORIN; DILTIAZEM; LIM PROTEIN; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 2; MYOSIN BINDING PROTEIN C; MYOSIN HEAVY CHAIN BETA; MYOSIN LIGHT CHAIN 2; TACROLIMUS; TROPONIN C; TROPONIN T;

CALCIUM CELL LEVEL; CELL STRESS; DIAGNOSTIC VALUE; DRUG MECHANISM; GENE MUTATION; GENETIC RISK; GENOTYPE PHENOTYPE CORRELATION; HEART MUSCLE CELL; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SARCOMERE;

CALCIUM; CARDIOMYOPATHY, HYPERTROPHIC; GENETIC ASSOCIATION STUDIES; HUMANS; MUTATION; SARCOMERES;

EID: 77952157390     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3283375698     Document Type: Review

References (47)

1. Maron BJ, Gardin JM, Flack JM, et al. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. Circulation 1995;92:785-789.
2. Seidman JG, Seidman CE. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001;104:557-567.
3. Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell 1990;62:999-1006.
4. Alcalai R, Seidman JG, Seidman CE. Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics. J Cardiovasc Electrophysiol 2008;19:104-110.
5. Richard P, Charron P, Carrier L, et al. Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy. Circulation 2003;107:2227-2232.
6. Morita H, Larson MG, Barr SC, et al. Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study. Circulation 2006;113:2697-2705.
7. Morita H, Rehm HL, Menesses A, et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med 2008;358:1899-1908. This is the first study that demonstrated that unexplained hypertrophy that occurs at a very young age is often due to HCM mutations. A correlate of this observation is that genetic testing is valuable in HCM that typically presents after adolescence and also in pediatric cardiomyopathies.
8. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol 2009;54:201-211.
9. Landstrom AP, Parvatiyar MS, Pinto JR, Marquardt ML, et al. Molecular and functional characterization of novel hypertrophic cardiomyopathy susceptibility mutations in TNNC1-encoded troponin C. J Mol Cell Cardiol 2008;45:281-288.
10. Pinto JR, Parvatiyar MS, Jones MA, et al. A functional and structural study of troponin C mutations related to hypertrophic cardiomyopathy. J Biol Chem 2009;284:19090-19100.
11. Satoh M, Takahashi M, Sakamoto T, et al. Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. Biochem Biophys Res Commun 1999;262:411-417.
12. Geier C, Perrot A, Ozceli KC, et al. Mutations in the human muscle LIM protein gene in families with hypertrophic cardiomyopathy. Circulation 2003;107:1390-1395.
13. Geier C, Gehmlich K, Ehler E, et al. Beyond the sarcomere: CSRP3 mutations cause hypertrophic cardiomyopathy. Hum Mol Genet 2008;17:2753-2765.
14. Hayashi T, Arimura T, Itoh-Satoh M, et al. Tcapgene mutations in hypertrophic cardiomyopathy and dilated cardiomyopathy. J Am Coll Cardiol 2004;44:2192-2201.
15. Osio A, Tan L, Chen SN, et al. Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy. Circ Res 2007;100:766-768.
16. Matsumoto Y, Hayashi T, Inagaki N, et al. Functional analysis of titin/connectin N2-B mutations found in cardiomyopathy. J Muscle Res Cell Motil 2005;26:367-374.
17. Arimura T, Matsumoto Y, Okazaki O, et al. Structural analysis of obscurin gene in hypertrophic cardiomyopathy. Biochem Biophys Res Commun 2007;362:281-287. (Pubitemid 47337088)
18. Arad M, Maron BJ, Gorham JM, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005;352:362-372.
19. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:288-293.
20. Wain LV, Armour JA, Tobin MD. Genomic copy number variation, human health, and disease. Lancet 2009;374:340-350.
21. Hastings PJ, Lupski JR, Rosenberg SM, Ira G. Mechanisms of change in gene copy number. Nat Rev Genet 2009;10:551-564.
22. van Dijk SJ, Dooijes D, dos Remedios C, et al. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 2009;119:1473-1483. This study demonstrated that HCM mutations engineered into mice, which reduced myosin-binding protein-C levels, contributed to altered cardiac function in HCM.
23. Marston S, Copeland O, Jacques A, Livesey K, et al. Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ Res 2009;105:219-222. This is the first study to show reduced levels of myosin-binding protein-C in human myectomy samples from HCM patients with MYPBC3 gene mutations.
24. Perkins MJ, Van Driest SL, Ellsworth EG, et al. Gene-specific modifying effects of pro-LVH polymorphisms involving the renin-angiotensin-aldosterone system among 389 unrelated patients with hypertrophic cardiomyopathy. Eur Heart J 2005;26:2457-2462.
25. Bos JM, Theis JL, Tajik AJ, et al. Relationship between sex, shape, and substrate in hypertrophic cardiomyopathy. Am Heart J 2008;155:1128-1134.
26. Maron BJ, McKenna WJ, Danielson GK, et al., Task Force on Clinical Expert Consensus Documents. American College of Cardiology; Committee for Practice Guidelines. European Society of Cardiology. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol 2003;42:1687-1713.
27. Olivotto I, Girolami F, Ackerman MJ, et al. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy. Mayo Clin Proc 2008;83:630-638.
28. Ackerman MJ, VanDriest SL, Ommen SR, et al. Prevalence and agedependence of malignant mutations in the beta-myosin heavy chain and troponin T genes in hypertrophic cardiomyopathy: a comprehensive outpatient perspective. J Am Coll Cardiol 2002;39:2042-2048.
29. Kokado H, Shimizu M, Yoshio H, et al. Clinical features of hypertrophic cardiomyopathy caused by aLys183 deletion mutation in the cardiac troponin I gene. Circulation 2000;102:663-669.
30. Dhandapany PS, Sadayappan S, Xue Y, et al. A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia. Nat Genet 2009;41:187-191. This study defines a very common HCM mutation that affects approximately 4% of individuals with ancestry from South India. Individuals with this mutation have significantly increased risk for developing heart failure.
31. Tyska MJ, Hayes E, Giewat M, et al. Single-molecule mechanics of R403Q cardiac myosin isolated from the mouse model of familial hypertrophic cardiomyopathy. Circ Res 2000;86:737-744.
32. 2+ homeostasis differentially determine the progression of cTnT-related cardiomyopathies in murine models. Am J Physiol Heart Circ Physiol 2009; 297: H614-626.
33. Hernandez OM, Szczesna-Cordary D, Knollmann BC, et al. F110I and R278C troponin T mutations that cause familial hypertrophic cardiomyopathy affect muscle contraction in transgenic mice and reconstituted human cardiac fibers. J Biol Chem 2005;280:37183-37194.
34. Volkmann N, Lui H, Hazelwood L, et al. The R403Q myosin mutation implicated in familial hypertrophic cardiomyopathy causes disorder at the actomyosin interface. PLoS One 2007; 2: e1123.
35. 2+ sensitization causes susceptibility to cardiac arrhythmia in mice. J Clin Invest 2008;118:3893-3903.
36. Lombardi R, Rodriguez G, Chen SN, et al. Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in atransgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation 2009;119:1398-1407. This study showed that reducing oxidative stress in a rabbit model of HCM decreased hypertrophy and fibrosis. If confirmed in human patients, this would provide new treatment strategies in HCM.
37. Backs J, Backs T, Neef S, et al. The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc Natl Acad Sci USA 2009;106:2342-2347.
38. Semsarian C, Ahmad I, Giewat M, et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest 2002;109:1013-1020.
39. Czubryt MP, Olson EN. Balancing contractility and energy production: the role of myocyte enhancer factor 2 (MEF2) in cardiac hypertrophy. Recent Prog Horm Res 2004;59:105-124.
40. Molkentin JD, Lu JR, Antos CL, et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1998;93:215-228.
41. Fatkin D, McConnell BK, Mudd JO, et al. An abnormal Ca (2+) response in mutant sarcomere protein-mediated familial hypertrophic cardiomyopathy. J Clin Invest 2000;106:1351-1359.
42. Petersen SE, Jerosch-Herold M, Hudsmith LE, et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation 2007;115:2418-2425.
43. Maron MS, Olivotto I, Maron BJ, et al. The case for myocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol 2009;54:866-875.
44. Ino T, Nishimoto K, Okubo M, et al. Apoptosis as a possible cause of wall thinning in end-stage hypertrophic cardiomyopathy. Am J Cardiol 1997;79:1137-1141.
45. Kim JB, Porreca GJ, Song L, et al. Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy. Science 2007;316:1481-1484.
46. Hasegawa K, Fujiwara H, Doyama K, et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993;88:372-380.
47. Senthil V, Chen SN, Tsybouleva N, et al. Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res 2005;97:285-292.